Healthcare

18:55

                            Nvidia collaborates with Novo Nordisk and the Danish Center for Artificial Intelligence Innovation (DCAI) to advance drug discovery
                        
                            Nvidia is collaborating with Novo Nordisk and the Danish Center for Artificial Intelligence Innovation (DCAI) to advance drug discovery.
                        
16:02

                            Novo Nordisk's US stock rose more than 2% before the market opened
                        
                            Novo Nordisk's U.S. shares rose more than 2% in pre-market trading after media reports that Parvus Asset Management was increasing its stake in Novo Nordisk.
                        
09:46

                            Hong Kong-listed pharmaceutical stocks fluctuated upward; Tigermed rose more than 7%
                        
                            Hong Kong-listed pharmaceutical stocks fluctuated upward, with Tiger Pharmaceuticals rising more than 7%, CStone Pharmaceuticals and Corning Life Sciences both rising nearly 6%, Zhaoyan Pharmaceutical rising more than 5.5%, and WuXi Biologics rising more than 4%.
                        
10:07

                            Hong Kong-listed biopharmaceutical stocks fluctuated and rose during the session; GenScript Biopharma rose more than 10%
                        
                            Hong Kong-listed biopharmaceutical stocks fluctuated upward during intraday trading, with GeneScript Biopharma rising more than 10%, InnoCare Pharma rising more than 9%, Tiger Pharmaceuticals rising more than 6%, Junshi Biosciences rising more than 5%, and WuXi Biologics rising more than 4%.
                        
09:37

                            The three major A-share indices turned down at the beginning of trading
                        
                            The three major A-share indices turned downward in early trading, with medical services, weight loss drugs and dairy sectors leading the decline.
                        
09:36

                            The three major A-share indices turned downward in early trading, with medical services, weight loss drugs and dairy sectors leading the decline.
                        
16:37

                            FTSE Russell announced the results of the June 2025 quarterly review. Jiangsu Bank was included in the FTSE China A50 Index and Great Wall Motor was excluded; BeiGene, Yili Group, SAIC Group, SERES, Huichuan Technology and other stocks were included in the list of alternative stocks.
                        
16:37

                            FTSE Russell announces June 2025 quarterly review results, FTSE China A50 Index includes Jiangsu Bank
                        
                            FTSE Russell announced the results of the June 2025 quarterly review. Jiangsu Bank was included in the FTSE China A50 Index and Great Wall Motor was excluded; BeiGene, Yili Group, SAIC Group, SERES, Huichuan Technology and other stocks were included in the list of alternative stocks.
                        
11:43

                            Kangfang Bio denies selling "clinical research drugs" to patients: sales staff forged materials to defraud the company of several drugs
                        
                            Recently, "clinical trial anticancer drugs entering the market" have attracted industry attention, and the drug involved is Kangfang Biopharma's cardunilimab. On June 4, Kangfang Biopharma provided reporters with a "Statement on News Reports on a Cervical Cancer Patient in Chongqing Using the Company's Drugs", stating that after investigation and verification: the company has never charged patient Li Moumei any fees for the clinical research drugs used by Li Moumei, and the company's sales staff have not charged any fees to the patient Li Moumei. In other words, there is no situation where the patient "spends money to buy clinical research drugs". The statement mentioned that the company's Chongqing sales staff forged research project documents and hospital ethics approval materials, and defrauded several drugs from the company in the name of post-marketing clinical research initiated by researchers, and gave them to patient Li Moumei for free. According to the sales staff: the drug was provided to Li Moumei for free many times, mainly because they considered that Li Moumei's ability to pay was very limited, and the efficacy of cardunilimab injection has been good since she used it. Kangfang Bio emphasized that the drugs obtained free of charge by patient Li Moumei were produced strictly in accordance with national GMP standards and were subject to the same strict drug quality management requirements as the company's commercially sold products.
                        
11:16

                            Eli Lilly and Camurus reach agreement to jointly develop drugs for obesity and diabetes
                        
                            Eli Lilly has signed a licensing and development agreement with Camurus, under which the two parties will jointly develop long-acting insulinotropic drugs for the treatment of obesity, diabetes and other metabolic diseases based on Camurus' FluidCrystal technology. The agreement allows Eli Lilly to develop up to four proprietary drug compounds, including GIP/GLP-1 receptor agonists, GIP/glucagon/GLP-1 receptor agonists, and options including amylin receptor agonists. At the same time, according to the agreement, Camurus is eligible for potential development and sales milestone payments of up to $870 million and mid-single-digit royalties.
                        
21:46

                            Novo Nordisk (NVO.N) narrowed its losses to 1.4%.
                        
21:45

                            Use of the diet pill Wegovy has risen 50% among American teenagers.
                        
20:13

                            BioNTech's U.S. stock price once rose nearly 12% before the market opened
                        
                            BioNTech's U.S. stock price once rose nearly 12% before the market opened. The company closed up more than 18% in the previous trading day. Multinational pharmaceutical giant Bristol-Myers Squibb announced that it had reached a licensing agreement with German biotechnology company BioNTech for a new generation of anti-cancer drug BNT327, with milestone payments of up to $11.1 billion.
                        
17:02

                            WuXi AppTec: Repurchased 6.6828 million shares with a total capital of RMB 400 million
                        
                            WuXi AppTec announced that the company held a board meeting on April 8, 2025 to review and approve the share repurchase plan, planning to use 1 billion yuan of funds to repurchase shares through centralized bidding to maintain the company's value and shareholders' interests. As of May 31, 2025, the company has repurchased a total of 6.6828 million shares, accounting for 0.2314% of the company's total share capital, with a repurchase price range of 52.52 yuan/share to 64.71 yuan/share, and a total of 400 million yuan in funds (excluding transaction fees). The company will continue to implement repurchases based on market conditions and disclose relevant progress in a timely manner.
                        
16:38

                            The National Medical Products Administration conditionally approved the marketing of Zenedatumumab for injection
                        
                            The National Medical Products Administration has conditionally approved the marketing of Zenidatuzumab for injection (trade name: Bhean) submitted by BeiGene (Suzhou) Biotechnology Co., Ltd. through the priority review and approval procedure. It is suitable for patients with unresectable locally advanced or metastatic biliary tract cancer with high HER2 expression (IHC3+) who have previously received systemic treatment. The launch of this product provides a new treatment option for related patients.
                        
1749639353
118906
3

Email Subscription

Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.

Trends

AI AI Tesla bitcoin Nvidia Xiaomi Apple Alibaba Tencent Huawei

Weekly Highlights

                                    Hong Kong stocks opened: Hang Seng Index opened 0.14% higher, Hang Seng Technology Index opened 0.13% higher
                            2025-06-06

                                    A U.S. appeals court rejected Apple's (AAPL.O) request to suspend an order on App Store reforms in its lawsuit against Epic Games, court documents showed.
                            2025-06-05

                                    Cainiao continues to deploy logistics + AI and joins hands with China Eastern Airlines to build the world's first smart hangar
                            2025-06-06

                                    Project establishment and formulation of safety requirements for combined driving assistance systems for intelligent connected vehicles
                            2025-06-04

                                    Lucid and Graphite One Sign Graphite Material Supply Agreement to Strengthen Supply Chain in the U.S.
                            2025-06-04